This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

A Study Comparing the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution With PREPOPIK® for Colon Cleansing in Preparation for Colonoscopy

This study is currently recruiting participants.
See Contacts and Locations
Verified June 2017 by Ferring Pharmaceuticals
Sponsor:
Information provided by (Responsible Party):
Ferring Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT03017235
First received: January 9, 2017
Last updated: June 19, 2017
Last verified: June 2017
  Purpose
The purpose of this study is to compare the Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution with PREPOPIK® for colon cleansing in adult subjects undergoing colonoscopy.

Condition Intervention Phase
Bowel Preparation Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Outcomes Assessor
Primary Purpose: Other
Official Title: A Randomized, Assessor-Blinded, Multi-Center Study Investigating the Efficacy, Safety, and Tolerability of Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution Versus Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Powder for Oral Solution (PREPOPIK®) for Colon Cleansing in Preparation for Colonoscopy

Resource links provided by NLM:


Further study details as provided by Ferring Pharmaceuticals:

Primary Outcome Measures:
  • Proportion of subjects classified as a responder defined by "excellent" or "good" [ Time Frame: At day of colonoscopy ]
    Measured by the Modified Aronchick scale


Secondary Outcome Measures:
  • Proportion of subjects classified as a responder defined by a score ≥2 in the right segment of the colon [ Time Frame: At day of colonoscopy ]
    Measured by the Boston Bowel Preparation Scale (BBPS)

  • Proportion of subjects classified as a responder defined by a score ≥2 in the transverse segment of the colon [ Time Frame: At day of colonoscopy ]
    Measured by the BBPS

  • Proportion of subjects classified as a responder defined by a score ≥2 in the left segment of the colon [ Time Frame: At day of colonoscopy ]
    Measured by the BBPS

  • Frequency of each category on the Subject Tolerability Questionnaire [ Time Frame: At day of colonoscopy ]
    Measured by the Mayo Clinic Bowel Prep Tolerability Questionnaire

  • Incidence of treatment-emergent adverse events(AEs) [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]
    Collected as any AE that begins during the treatment period defined as the period during which a subject receives IMP

  • Clinically significant changes in vital signs [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]
    Blood pressure and pulse will be measured after at least 5 minutes of rest in supine position and after 3 minutes in standing position

  • Clinically significant changes in electrocardiogram (ECG) [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]
    Measured by standard 12-lead ECG

  • Clinically significant changes in laboratory values [ Time Frame: From baseline (screening) up to day 28 after colonoscopy ]
    Rated by the investigator based on out of range laboratory values


Estimated Enrollment: 900
Actual Study Start Date: February 20, 2017
Estimated Study Completion Date: October 2017
Estimated Primary Completion Date: September 2017 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: NaP/MC Oral Solution
Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid (NaP/MC) Oral Solution
Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Acid Oral Solution
Supplied as ready-to-drink without further reconstitution before administration
Active Comparator: PREPOPIK® Drug: Sodium Picosulfate, Magnesium Oxide and Anhydrous Citric Powder
Supplied as two packets per subject. Subjects will be instructed to reconstitute the medication by combining the contents of one packet with approximately five (5) ounces of cold water and stirring for two to three minutes.
Other Names:
  • PREPOPIK®
  • PicoPrep®

  Eligibility

Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Male or non-pregnant female subjects aged 18 to 80 years, inclusive, being scheduled to undergo elective colonoscopy
  • Females of childbearing potential must agree to use an adequate contraception during the course of the trial. Accepted forms of contraception are: i.e., implants, injectables, hormonal intrauterine device, combined hormonal contraceptives, sexual abstinence, and vasectomized sexual partner. Premenopausal women who are of childbearing potential must have a negative serum pregnancy test result at screening and a negative urine pregnancy test result at randomization prior to colonoscopy. In the case of oral contraceptive use, women should have been taking the same pill consistently for a minimum of twelve (12) weeks before taking study medication. Sterilized or postmenopausal women may also participate. Women are considered to be postmenopausal and are not considered to be of childbearing potential if they have had twelve (12) months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or have had surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation.
  • An average of at least 3 spontaneous bowel movements per week for one month prior to the colonoscopy

Exclusion Criteria:

  • Known or suspected gastrointestinal obstruction, perforation, ileus, or gastric retention
  • Acute intestinal or gastric ulceration
  • Severe acute inflammatory bowel disease (IBD), toxic colitis, or toxic megacolon
  • Undergoing colonoscopy for foreign body removal or decompression
  • Reduced level of consciousness or inability to swallow without aspiration
  • Any prior colorectal surgery, excluding appendectomy, hemorrhoid surgery, or prior endoscopic procedures
  • Upper gastrointestinal surgery (gastrectomy, gastric banding, gastric by-pass)
  • Uncontrolled angina and/or myocardial infarction (MI) within last three months, congestive heart failure (CHF), uncontrolled hypertension, or ascites
  • Severely reduced renal function (<30 mL/min/1.73 m2)
  • Pregnant or lactating women
  • Any clinically relevant abnormal findings in medical history, physical examination, vital signs, ECG, clinical chemistry, hematology, coagulation, or urinalysis at Screening Visit 1
  • Rhabdomyolysis
  • Chronic nausea and vomiting
  • Hypermagnesemia
  • Undergoing treatment with Lithium
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT03017235

Contacts
Contact: Clinical Development Support +1 833-548-1402 (US/Canada) DK0-Disclosure@ferring.com
Contact: Clinical Development Support +1 862-286-5200 (outside US) DK0-Disclosure@ferring.com

Locations
United States, Alabama
Clinical Research Associates Recruiting
Huntsville, Alabama, United States, 35801
United States, California
Associated Gastroenterology Medical Group Recruiting
Anaheim, California, United States, 92801
GW Research, Inc. Recruiting
Chula Vista, California, United States, 91910
Precision Research Institute Recruiting
San Diego, California, United States, 92114
United States, Connecticut
Connecticut Clinical Research Foundation Recruiting
Bristol, Connecticut, United States, 06010
United States, Florida
Florida Clinical Research Group Recruiting
Clearwater, Florida, United States, 33759
Nature Coast Clinical Research Recruiting
Inverness, Florida, United States, 34452
United States, New York
Long Island Gastrointestinal Research Group LLC Recruiting
Great Neck, New York, United States, 11023
United States, North Carolina
Kinston Medical Specialists, PA Recruiting
Kinston, North Carolina, United States, 28501
Wake Research Associates, LLC Recruiting
Raleigh, North Carolina, United States, 27612
United States, Pennsylvania
Hillmont GI Recruiting
Flourtown, Pennsylvania, United States, 19031
United States, Utah
Advanced Research Institute Recruiting
Ogden, Utah, United States, 84405
Canada
Hotel Dieu Hospital Recruiting
Kingston, Canada, K7L 5G2
Canadian Phase Onward, Inc. Recruiting
Toronto, Canada, M3J 2C5
Sponsors and Collaborators
Ferring Pharmaceuticals
Investigators
Study Director: Clinical Development Support Ferring Pharmaceuticals
  More Information

Responsible Party: Ferring Pharmaceuticals
ClinicalTrials.gov Identifier: NCT03017235     History of Changes
Other Study ID Numbers: 000253
Study First Received: January 9, 2017
Last Updated: June 19, 2017

Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No

Additional relevant MeSH terms:
Pharmaceutical Solutions
Citric Acid
Picosulfate sodium
Magnesium Oxide
Anticoagulants
Calcium Chelating Agents
Chelating Agents
Sequestering Agents
Molecular Mechanisms of Pharmacological Action
Cathartics
Gastrointestinal Agents
Antacids

ClinicalTrials.gov processed this record on July 17, 2017